KIRKLAND 4 – Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY® COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY® vaccine targets the Omicron KP.2 variant, one of the most recently circulating SARS-CoV-2 lineages. The adapted COVID-19 vaccine will be available in Canada as a single dose for individuals 5 …
Product description Brand name COMIRNATY that has been approved recently by Health Canada Company name BioNTech Manufacturing GmbH Ingredient mRNA encoding SARS-CoV-2 spike protein, 5’ [m27,3’-OGppp(m12’-O)ApG] cap, 110-nucleotide 3′ poly(A) tail with a 10-nucleotide linker sequence. This product (COMIRNATY) includes an update to the antigen composition (variant Omicron KP.2) and replaces COMIRNATY Omicron XBB.1.5 (raxtozinameran).
Main – An updated COVID-19 vaccine is tailored by Pfizer-BionTech to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older. You should NOT get COMIRNATY® (COVID-19 Vaccine, mRNA) if you had a severe allergic reaction to a previous dose of COMIRNATY or any Pfizer-BioNTech COVID-19 vaccine or to any ingredient …
Main – Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA)), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies’ Omicron KP.2-adapted …
KIRKLAND, QUEBEC and MAINZ, GERMANY – Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that COMIRNATY, the Pfizer-BioNTech COVID-19 Vaccine, has been named the 2023 winner of the Prix Galien Canada Innovative Product Award. COMIRNATY is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in …
Ottawa – All COVID-19 vaccines authorized in Canada are proven safe, effective and of high quality. Name: AstraZeneca Vaxzevria® COVID-19 vaccine Manufacturer: AstraZeneca Canada Inc and Verity/SII (COVISHIELD) Type: Viral vector-based Status: Approved by Health Canada Approved for: Age 18 and older How it’s given: Injection in muscle (usually the upper arm) Number of doses: 2 doses Note: The COVISHIELD version of this vaccine provided a temporary …
